3487 related articles for article (PubMed ID: 20113825)
1. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Ismael G; Hegg R; Muehlbauer S; Heinzmann D; Lum B; Kim SB; Pienkowski T; Lichinitser M; Semiglazov V; Melichar B; Jackisch C
Lancet Oncol; 2012 Sep; 13(9):869-78. PubMed ID: 22884505
[TBL] [Abstract][Full Text] [Related]
4. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
6. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
7. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
9. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
10. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Smith I; Procter M; Gelber RD; Guillaume S; Feyereislova A; Dowsett M; Goldhirsch A; Untch M; Mariani G; Baselga J; Kaufmann M; Cameron D; Bell R; Bergh J; Coleman R; Wardley A; Harbeck N; Lopez RI; Mallmann P; Gelmon K; Wilcken N; Wist E; Sánchez Rovira P; Piccart-Gebhart MJ;
Lancet; 2007 Jan; 369(9555):29-36. PubMed ID: 17208639
[TBL] [Abstract][Full Text] [Related]
11. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
15. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer.
Paluch-Shimon S; Wolf I; Goldberg H; Evron E; Papa MZ; Shabtai M; Barsuk D; Yosepovich A; Modiano T; Catane R; Kaufman B
Acta Oncol; 2008; 47(8):1564-9. PubMed ID: 18607846
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
Chang HR
Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
[TBL] [Abstract][Full Text] [Related]
19. [Breast cancer: HER2 changes one's cards on the table].
Lopez M
Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
Pierga JY; Petit T; Delozier T; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roché H; Bachelot T; Charafe-Jauffret E; Pavlyuk M; Kraemer S; Bidard FC; Viens P
Lancet Oncol; 2012 Apr; 13(4):375-84. PubMed ID: 22377126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
